ARA-290 is a synthetic peptide engineered from the helix B region of erythropoietin (EPO) — specifically the 11-amino acid sequence that activates EPO's tissue-protective receptor complex without triggering the erythropoietic effects that make EPO dangerous as a doping agent. By isolating the tissue-protective signaling arm of EPO from its red-blood-cell-stimulating arm, ARA-290 delivers neuroprotection, anti-inflammation, and tissue repair without any blood-thickening risk.

The Two Faces of Erythropoietin

Erythropoietin (EPO) is well known as the "blood doping" hormone — it stimulates red blood cell production (erythropoiesis) by binding the homodimeric EPOR (EPO receptor) on erythroid progenitor cells in bone marrow. This is EPO's erythropoietic function, and it is responsible for both EPO's therapeutic role in anemia and its abuse in endurance sports.

However, EPO has a completely separate tissue-protective function: it binds a heterodimeric receptor complex (EPOR/βcR — EPO receptor paired with the beta common receptor, also known as CD131) in non-hematopoietic tissues. This receptor complex, expressed in neurons, cardiac tissue, kidney, retina, and immune cells, mediates EPO's anti-apoptotic, anti-inflammatory, and tissue-repair effects.

ARA-290 (also known as Cibinetide) was designed specifically to activate only the EPOR/βcR complex — it has minimal affinity for the homodimeric EPOR that drives erythropoiesis. This selectivity provides all of EPO's protective benefits with none of its blood-thickening risks.

Neuroprotective Applications: Diabetic Neuropathy

ARA-290's most clinically developed application is peripheral neuropathy — particularly the pain and nerve damage associated with diabetes and other metabolic conditions. Phase 2 clinical trials showed: - Significant reduction in neuropathic pain scores - Improvements in corneal nerve fiber density (measurable nerve regeneration) - Reduction in small-fiber neuropathy measures - The corneal nerve data is particularly significant — it provides objective evidence of actual nerve repair rather than just symptomatic pain relief

Peripheral neuropathy affects >30 million Americans and has essentially no disease-modifying treatments — existing medications only manage symptoms. ARA-290 is among the few compounds showing objective nerve regeneration in clinical trials.

Anti-Inflammatory Mechanism

EPOR/βcR activation by ARA-290 produces: - Reduction of NF-κB activation (the master inflammatory transcription factor) - Decreased pro-inflammatory cytokine production (IL-6, TNF-α, IL-1β) - Increased anti-inflammatory IL-10 - Activation of Jak2/STAT3 protective signaling in injured cells - Inhibition of apoptosis in neurons, cardiomyocytes, and renal cells under stress

This anti-inflammatory and anti-apoptotic profile makes ARA-290 broadly relevant for any condition involving tissue damage from inflammation or ischemia.

Cardiac Protection

Cardiac EPOR/βcR activation provides cardioprotection in ischemia/reperfusion models — similar to the mechanism of hexarelin (which activates GHS-R1a on cardiac tissue). ARA-290's cardiac protection adds another dimension to its tissue-protective applications beyond neuropathy.

Research Status

ARA-290 is being developed by Araim Pharmaceuticals and has completed Phase 2 trials for diabetic neuropathy and sarcoidosis-associated small-fiber neuropathy. Phase 3 trials are in planning stages. The sarcoidosis data showed significant improvements in corneal nerve density and pain — conditions with extremely limited treatment options.